THE NovoTTF-100L™ SYSTEM IS NOW FDA approved to treat mesothelioma*
*Unresectable, locally advanced or metastatic, malignant pleural mesothelioma.
PUT GBM ON PAUSE
PUT GBM ON PAUSE
Patient-reported data collected per EORTC QLQ-C30 at baseline and Months 3, 6, 9, and 12. The 30-question survey covered 5 daily-functioning domains (Physical, Role, Social, Emotional, and Cognitive).
The updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers now include alternating electric field therapy (Optune) in combination with temozolomide (TMZ) following maximal safe resection and standard brain radiation therapy with concurrent TMZ as a Category 1 recommended treatment option for patients with newly diagnosed supratentorial glioblastoma (GBM) and good performance status.* There is uniform NCCN consensus for this recommendation based on high-level evidence (Category 1).
"I was initially concerned because I didn't fully understand what it would be like. But, I overcame my fears ... [and] in a matter of weeks, I was at ease toting the backpack."-JB, Optune user
*The NCCN defines good performance as Karnofsky Performance Score (KPS) ≥60. The trial for which the IFU is based used an eligibility criteria of KPS ≥70. The NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
†Daily-functioning domains evaluated were Physical, Role, Social, Emotional, and Cognitive as determined by the EORTC QLQ-C30 core questionnaire.
References: 1. Optune Instructions for Use. Novocure 2019. 2. Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with Tumor-Treating Fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(4):495–504. 3. Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol. 2019;141(2):467-473. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers. V.1.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed March 5, 2019. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.
Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).